Advertisement
Screener

ENTERA BIO LTD. (ENTX) Graph

ENTX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Cost of revenue $0.00; Research and development $3.20M; Selling, general and administrative $124.00K.
  • 2026-03-31: Revenue $0.00; Cost of revenue $0.00; Research and development $2.25M; Selling, general and administrative $128.00K.
  • 2025-12-31: Revenue $0.00*; Cost of revenue $0.00*; Research and development $1.72M*; Selling, general and administrative $54.00K*.
  • 2025-09-30: Revenue $0.00; Cost of revenue $0.00; Research and development $1.64M; Selling, general and administrative $122.00K.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ENTX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Cost of revenue$0.00Gross profit$0.00Operating expenses$4.56MOperating income-$4.56MResearch & development$3.20MSelling, general& administrative$124.00KNet income-$7.31M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$0.00$0.00$3.20M$124.00K$4.56M(m)-$7.31M
2026-03-31$0.00$0.00$2.25M$128.00K$3.54M(m)-$3.50M
2025-12-31$0.00*$0.00*$1.72M*$54.00K*$3.04M*(m)(m)
2025-09-30$0.00$0.00$1.64M$122.00K$3.26M(m)-$3.20M
2025-06-30$0.00$0.00$1.52M$103.00K$2.67M(m)-$2.66M
2025-03-31$42.00K$42.00K$1.12M$123.00K$2.56M(m)-$2.57M
2024-09-30$42.00K$42.00K$1.48M$62.00K$3.02M$0.00-$3.02M
2024-06-30$57.00K$48.00K$1.09M$134.00K$2.17M(m)-$2.15M
2024-03-31$0.00$0.00$735.00K(m)$2.06M(m)-$2.02M
2023-09-30$0.00$0.00$1.37M(m)$2.39M$29.00K-$2.38M
2023-06-30$0.00$0.00$1.21M(m)$2.33M$0.00-$2.33M
2023-03-31$0.00$0.00$931.00K(m)$2.21M$0.00-$2.19M
2022-09-30$8.00K$6.00K$1.41M(m)$2.87M$194.00K-$3.07M
2022-06-30$44.00K$33.00K$1.39M(m)$3.26M-$4.00K-$3.19M
2022-03-31$68.00K$54.00K$1.69M(m)$3.85M-$7.00K-$3.78M
2021-09-30$140.00K$65.00K$1.77M(m)$3.29M-$13.00K-$3.21M
2021-06-30$109.00K$99.00K$1.23M(m)$2.58M-$17.00K-$2.58M
2021-03-31$157.00K$73.00K$1.12M(m)$2.42M-$14.00K-$2.30M
2020-06-30(m)(m)$2.01M(m)(m)(m)(m)
2019-06-30(m)(m)$1.41M(m)(m)(m)(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$0.00$0.00$5.45M$252.00K$8.10M(m)-$10.82M
2025-06-30$42.00K$42.00K$2.64M$226.00K$5.23M(m)-$5.22M
2024-06-30$57.00K$48.00K$1.82M$214.00K$4.24M(m)-$4.16M
2023-06-30$0.00$0.00$2.14M(m)$4.54M$0.00-$4.51M
2022-06-30$112.00K$87.00K$3.08M(m)$7.11M-$11.00K-$6.97M
2021-06-30$266.00K$172.00K$2.35M(m)$5.00M-$31.00K-$4.87M
2020-06-30(m)(m)$3.62M(m)(m)(m)(m)
2019-06-30(m)(m)$3.45M(m)(m)(m)(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$42.00K$42.00K$4.29M$344.00K$8.49M(m)-$8.42M
2024-09-30$99.00K$90.00K$3.30M$244.00K$7.26M$0.00-$7.18M
2023-09-30$0.00$0.00$3.51M(m)$6.93M$29.00K-$6.89M
2022-09-30$120.00K$93.00K$4.50M(m)$9.98M$183.00K-$10.04M
2021-09-30$406.00K$237.00K$4.12M(m)$8.30M-$44.00K-$8.09M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$42.00K$42.00K$6.00M$398.00K$11.53M$0.00-$11.44M
2024-12-31$181.00K$172.00K$4.50M$340.00K$9.59M$14.00K-$9.54M
2023-12-31$0.00$0.00$4.51M(m)$8.89M$29.00K-$8.89M
2022-12-31$134.00K$101.00K$5.85M(m)$13.05M$137.00K-$13.07M
2021-12-31$571.00K$373.00K$6.77M(m)$12.41M-$59.00K-$12.19M
2020-12-31$365.00K$300.00K$6.38M(m)$11.23M$20.00K-$11.22M
2019-12-31(m)(m)$7.20M(m)(m)(m)(m)
2018-12-31(m)(m)$8.52M(m)(m)(m)(m)
2017-12-31(m)(m)$2.77M(m)(m)(m)(m)
2016-12-31(m)(m)$2.65M(m)(m)(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Zura Bio Ltd (ZURA)$0.398B-6.56
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33